Rate My Professor Peter Cabot

Professor Peter Cabot is the Professor and Head of School in the School of Pharmacy and Pharmaceutical Sciences at the University of Queensland, within the Faculty of Health and Behavioural Sciences. He holds a Doctor of Philosophy from the University of Queensland, completed in 1996 with a thesis titled 'Peripheral opioid binding sites in the rat and human lung: possible explanation for the relief of Dyspnoea by nebulized morphine', and a Bachelor of Applied Science from Charles Sturt University. Cabot joined the UQ School of Pharmacy staff in 1999 in his current position, following postdoctoral fellowships at Johns Hopkins University in Baltimore, USA, the National Institutes of Health in Baltimore, USA, and within the UQ School of Pharmacy.

The primary focus of Professor Cabot's research is the elucidation of peripheral mechanisms involved in analgesia associated with inflammation, with key discoveries highlighting the importance of the immune system in inflammatory pain. These findings have been published in high-impact journals including the Journal of Biological Chemistry, PAIN, Nature Medicine, and the Journal of Clinical Investigation. His research interests encompass opioids in inflammation as a translational scientist developing novel opioids and inflammatory mechanisms, biotransformation of opioids in disease, pain in inflammatory diseases, and natural products drug discovery. He is an affiliate of the Centre for Innovation in Pain and Health Research. Notable publications include 'Immune cell-derived beta-endorphin: Production, release, and control of inflammatory pain in rats' (1997, The Journal of Clinical Investigation), 'Pain control in inflammation governed by selectins' (1998, Nature Medicine), 'Morphine and tumor growth and metastasis' (2011, Cancer and Metastasis Reviews), 'C-reactive protein (CRP) is associated with chronic pain independently of biopsychosocial factors' (2024, The Journal of Pain), and 'Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy' (2023, Frontiers in Pharmacology). His contributions have advanced the understanding of immune-derived peripheral analgesia and pain modulation.